Screener
Rhythm Pharmaceuticals, Inc. RYTM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Deferred revenue | (145) | (1,286) |
| Other long-term assets, net | 435 | 102 |
| Accounts payable, accrued expenses and other liabilities | (5,618) | (3,633) |
| Net cash used in operating activities | (44,185) | (40,351) |
| Investing activities | ||
| Purchases of short-term investments | (42,199) | (33,521) |
| Maturities of short-term investments | 99,251 | 58,333 |
| Net cash provided by investing activities | 57,052 | 24,812 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s operating cash flow?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported operating cash flow of -$44.19M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s operating cash flow decreased by 9.5% year-over-year, from -$40.35M to -$44.19M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s operating cash flow has grown at a -5.7% compound annual growth rate (CAGR), from -$146M to -$115.68M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude